<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-05-17T00:18:33Z</responseDate><request verb="GetRecord" identifier="oai:repisalud.isciii.es:20.500.12105/18287" metadataPrefix="mets">https://repisalud.isciii.es/rest/oai/request</request><GetRecord><record><header><identifier>oai:repisalud.isciii.es:20.500.12105/18287</identifier><datestamp>2024-11-28T15:14:33Z</datestamp><setSpec>com_20.500.12105_15322</setSpec><setSpec>com_20.500.12105_2051</setSpec><setSpec>col_20.500.12105_16927</setSpec></header><metadata><mets xmlns="http://www.loc.gov/METS/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="&#xa;&#x9;&#x9;&#x9;&#x9;DSpace_ITEM_20.500.12105-18287" TYPE="DSpace ITEM" PROFILE="DSpace METS SIP Profile 1.0" xsi:schemaLocation="http://www.loc.gov/METS/ http://www.loc.gov/standards/mets/mets.xsd" OBJID="&#xa;&#x9;&#x9;&#x9;&#x9;hdl:20.500.12105/18287">
   <metsHdr CREATEDATE="2026-05-17T02:18:33Z">
      <agent ROLE="CUSTODIAN" TYPE="ORGANIZATION">
         <name>Repisalud</name>
      </agent>
   </metsHdr>
   <dmdSec ID="DMD_20.500.12105_18287">
      <mdWrap MDTYPE="MODS">
         <xmlData xmlns:mods="http://www.loc.gov/mods/v3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
            <mods:mods xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Borroto-Escuela, Dasiel O.</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Wydra, Karolina</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Fores-Pons, Ramon</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Vasudevan, Lakshmi</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Romero-Fernandez, Wilber</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Frankowska, Małgorzata</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Ferraro, Luca</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Beggiato, Sarah</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Crespo-Ramirez, Minerva</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Rivera, Alicia</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Rocha, Luisa L.</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Perez de la Mora, Miguel</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Stove, Christophe</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Filip, Małgorzata</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Fuxe, Kjell</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">authoraffiliation</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>[Borroto-Escuela,DO; Fores-Pons,R; Romero-Fernandez,W; Fuxe,K] Department of Neuroscience, Karolinska Institutet, Biomedicum, Stockholm, Sweden. [Wydra,K; Frankowska,M; Filip,M] Department of Drug Addiction Pharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland. [Vasudevan,L; Stove,CC] Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium. [Ferraro,L] Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy. [Beggiato,S] Department of Medical, Oral and Biotechnological Sciences, University of Chieti-Pescara, Chieti, Italy. [Crespo-Ramirez,M; Perez de la Mora,M] Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Mexico City, Mexico. [Rivera,A] Department of Cell Biology, University of Malaga, Instituto de Investigación Biomédica (IBIMA), Malaga, Spain. [Rocha,LL] Pharmacobiology Department, Center for Research and Advanced Studies, Mexico City, Mexico</mods:namePart>
               </mods:name>
               <mods:extension>
                  <mods:dateAccessioned encoding="iso8601">2024-02-19T15:26:30Z</mods:dateAccessioned>
               </mods:extension>
               <mods:extension>
                  <mods:dateAvailable encoding="iso8601">2024-02-19T15:26:30Z</mods:dateAvailable>
               </mods:extension>
               <mods:originInfo>
                  <mods:dateIssued encoding="iso8601">2021-03-15</mods:dateIssued>
               </mods:originInfo>
               <mods:identifier type="doi">10.3389/fphar.2021.627032</mods:identifier>
               <mods:identifier type="e-issn">1663-9812</mods:identifier>
               <mods:identifier type="journal">Frontiers in Pharmacology</mods:identifier>
               <mods:identifier type="other">http://hdl.handle.net/10668/4551</mods:identifier>
               <mods:identifier type="pubmedID">33790790</mods:identifier>
               <mods:identifier type="uri">http://hdl.handle.net/20.500.12105/18287</mods:identifier>
               <mods:abstract>The widespread distribution of heteroreceptor complexes with allosteric receptor-receptor interactions in the CNS represents a novel integrative molecular mechanism in the plasma membrane of neurons and glial cells. It was proposed that they form the molecular basis for learning and short-and long-term memories. This is also true for drug memories formed during the development of substance use disorders like morphine and cocaine use disorders. In cocaine use disorder it was found that irreversible A2AR-D2R complexes with an allosteric brake on D2R recognition and signaling are formed in increased densities in the ventral enkephalin positive striatal-pallidal GABA antireward neurons. In this perspective article we discuss and propose how an increase in opioid heteroreceptor complexes, containing MOR-DOR, MOR-MOR and MOR-D2R, and their balance with each other and A2AR-D2R complexes in the striatal-pallidal enkephalin positive GABA antireward neurons, may represent markers for development of morphine use disorders. We suggest that increased formation of MOR-DOR complexes takes place in the striatal-pallidal enkephalin positive GABA antireward neurons after chronic morphine treatment in part through recruitment of MOR from the MOR-D2R complexes due to the possibility that MOR upon morphine treatment can develop a higher affinity for DOR. As a result, increased numbers of D2R monomers/homomers in these neurons become free to interact with the A2A receptors found in high densities within such neurons. Increased numbers of A2AR-D2R heteroreceptor complexes are formed and contribute to enhanced firing of these antireward neurons due to loss of inhibitory D2R protomer signaling which finally leads to the development of morphine use disorder. Development of cocaine use disorder may instead be reduced through enkephalin induced activation of the MOR-DOR complex inhibiting the activity of the enkephalin positive GABA antireward neurons. Altogether, we propose that these altered complexes could be pharmacological targets to modulate the reward and the development of substance use disorders.</mods:abstract>
               <mods:language>
                  <mods:languageTerm authority="rfc3066">eng</mods:languageTerm>
               </mods:language>
               <mods:accessCondition type="useAndReproduction"/>
               <mods:subject>
                  <mods:topic>G protein-coupled receptor</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Mu opioid receptor</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Dopamine D2 receptor</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Adenosine A2A receptor</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Morphine use disorder</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Cocaine use disorder</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Oligomerization</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Morphine</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Neurons</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Enkephalins</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Receptores acoplados a proteínas G</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Receptores opioides mu</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Receptores de dopamina D2</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Receptor de adenosina A2A</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Morfina</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Trastornos relacionados con sustancias</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Cocaína</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Neuronas</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Encefalinas</mods:topic>
               </mods:subject>
               <mods:titleInfo>
                  <mods:title>The Balance of MU-Opioid, Dopamine D2 and Adenosine A2A Heteroreceptor Complexes in the Ventral Striatal-Pallidal GABA Antireward Neurons May Have a Significant Role in Morphine and Cocaine Use Disorders</mods:title>
               </mods:titleInfo>
               <mods:genre>research article</mods:genre>
            </mods:mods>
         </xmlData>
      </mdWrap>
   </dmdSec>
   <structMap LABEL="DSpace Object" TYPE="LOGICAL">
      <div TYPE="DSpace Object Contents" ADMID="DMD_20.500.12105_18287"/>
   </structMap>
</mets></metadata></record></GetRecord></OAI-PMH>